ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells

Area of Science:

• Oncology
• Immunotherapy
• Cancer Biology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy is a promising cancer treatment.
• Anaplastic lymphoma kinase (ALK) is a key driver in neuroblastoma and a potential therapeutic target.
• Selecting appropriate tumor antigens is crucial for CAR T-cell efficacy.

Purpose of the Study:

• To develop and evaluate ALK-targeted CAR T-cells (ALK.CAR-T) for neuroblastoma treatment.
• To investigate the efficacy of ALK.CAR-T cells alone and in combination with ALK inhibitors.
• To elucidate the mechanisms underlying the combination therapy's effectiveness.

Main Methods:

• Development of ALK.CAR-T cells.
• In vitro and in vivo testing of ALK.CAR-T cell monotherapy and combination therapy with ALK inhibitors in neuroblastoma models.
• Analysis of ALK expression and tumor response.

Main Results:

• ALK.CAR-T cells demonstrated potent monotherapy efficacy against neuroblastoma with high ALK expression without toxicity.
• Combination therapy of ALK inhibitors and ALK.CAR-T cells specifically enhanced efficacy in neuroblastoma with low ALK expression.
• ALK inhibitors were found to impair tumor growth and upregulate ALK expression, thereby improving ALK.CAR-T cell activity.

Conclusions:

• ALK.CAR-T cell therapy is effective against high-ALK expressing neuroblastomas.
• Combination therapy with ALK inhibitors offers a synergistic approach for treating low-ALK expressing neuroblastomas.
• Targeting ALK presents a viable strategy for enhancing neuroblastoma immunotherapy.